Patents by Inventor Francis Fang

Francis Fang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20230140327
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: September 29, 2022
    Publication date: May 4, 2023
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 11491163
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: November 8, 2022
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS
    Publication number: 20210171555
    Abstract: We provide diastereomerically pure or substantially diastereomerically pure activated phosphoramidochloridate morpholino nucleosides, methods of their preparation, and methods of their use in stereospecific coupling for stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs).
    Type: Application
    Filed: October 28, 2020
    Publication date: June 10, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi ENDO, Robert T. YU, Francis FANG, Hyeong Wook CHOI, Mingde SHAN
  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20210137936
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: September 25, 2020
    Publication date: May 13, 2021
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun HUANG, Hyeong Wook CHOI, Kristen SANDERS, Steven MATHIEU, Arani CHANDA, Francis FANG
  • Substituted phosphorodiamidate morpholino oligomers
    Patent number: 10836784
    Abstract: A phosphoramidochloridate morpholino monomer of the following formula is provided:
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: November 17, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Atsushi Endo, Robert T. Yu, Francis Fang, Hyeong Wook Choi, Mingde Shan
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 10821113
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 3, 2020
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • CHIRAL REAGENTS FOR PREPARATION OF SUBSTITUTED PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS
    Publication number: 20200115405
    Abstract: A method of preparation of stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs) of one of the following general formulas is provided.
    Type: Application
    Filed: September 17, 2019
    Publication date: April 16, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi ENDO, Robert T. YU, Francis FANG, Hyeong Wook CHOI, Mingde SHAN
  • Chiral reagents for preparation of substituted phosphorodiamidate morpholino oligomers
    Patent number: 10457698
    Abstract: A method of preparation of stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs) of one of the following general formulas is provided:
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: October 29, 2019
    Assignee: Eisai R&D Management Co., Ltd
    Inventors: Atsushi Endo, Robert T. Yu, Francis Fang, Hyeong Wook Choi, Mingde Shan
  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20190269692
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: February 8, 2019
    Publication date: September 5, 2019
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun HUANG, Hyeong Wook CHOI, Kristen SANDERS, Steven MATHIEU, Arani CHANDA, Francis FANG
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 10245269
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 2, 2019
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20180243316
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: December 11, 2017
    Publication date: August 30, 2018
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS
    Publication number: 20180222932
    Abstract: We provide diastereomerically pure or substantially diastereomerically pure activated phosphoramidochloridate morpholino nucleosides, methods of their preparation, and methods of their use in stereospecific coupling for stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs).
    Type: Application
    Filed: August 5, 2016
    Publication date: August 9, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi Endo, Robert T. Yu, Francis Fang, Hyeong Wook Choi, Mingde Shan
  • Imidazoazepinone compounds
    Patent number: 7985746
    Abstract: The invention relates to compounds of formula I: along with pharmaceutical compositions containing the same and methods of use thereof for the treatment of autoimmune disease.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: July 26, 2011
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Francis Fang, Shawn Schiller, Boris Seletsky, Mark Spyvee
  • METHOD OF MAKING IMIDAZOAZEPINONE COMPOUNDS
    Publication number: 20110065916
    Abstract: A method of making a compound of Formula I: is carried out by (a) providing a compound of Formula (II) or (III): wherein ring A is C3-14 aryl or C3-14 heteroaryl such as phenyl or furanyl, and then (b) combining the compound of Formula (II) or (III) with an acid to produce a compound of Formula I.
    Type: Application
    Filed: November 26, 2008
    Publication date: March 17, 2011
    Inventors: Mark Spyvee, Boris M. Seletsky, Shawn Schiller, Francis Fang
  • EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF
    Publication number: 20090291998
    Abstract: The present invention provides compounds having formula (1): wherein R1-R6, A, J, D, A, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.
    Type: Application
    Filed: March 3, 2009
    Publication date: November 26, 2009
    Inventors: Sergei Agoulnik, Kozo Akasaka, Francis Fang, Jean-Christophe Harmange, Lynn Hawkins, Yimin Jiang, Charles Johannes, Xiang-Yi Li, Pamela McGuinness, Erin A. Murphy, Shawn Schiller, Mary Vermeulen, Jiayi Wu
  • IMIDAZOAZEPINONE COMPOUNDS
    Publication number: 20090233906
    Abstract: The invention relates to compounds of formula (I): along with pharmaceutical compositions containing the same and methods of use thereof.
    Type: Application
    Filed: May 23, 2007
    Publication date: September 17, 2009
    Inventors: Francis Fang, Shawn Schiller, Boris Seletsky, Mark Spyvee
  • IMIDAZOAZEPINONE COMPOUNDS
    Publication number: 20090131405
    Abstract: The invention relates to compounds of formula I: along with pharmaceutical compositions containing the same and methods of use thereof for the treatment of autoimmune disease.
    Type: Application
    Filed: May 24, 2007
    Publication date: May 21, 2009
    Inventors: Francis Fang, Shawn Schiller, Boris Seletsky, Mark Spyvee
  • Luminacin analogs and uses thereof
    Publication number: 20080249320
    Abstract: The present invention provides compounds having formula (I) (and pharmaceutically acceptable derivatives thereof): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R14 and n are as defined herein.
    Type: Application
    Filed: April 9, 2008
    Publication date: October 9, 2008
    Inventors: Francis Fang, Charles Johannes, Ye Yao, Xiaojie (Jeff) Zhu
  • Laulimalide Analogs and Uses Thereof
    Publication number: 20070287745
    Abstract: The present invention provides compounds having formula I: and pharmaceutically acceptable derivatives thereof, wherein R1-R10, q, t, X0, X1, A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated with cellular hyperproliferation.
    Type: Application
    Filed: September 22, 2004
    Publication date: December 13, 2007
    Inventors: Brian Gallagher Jr, Charles Johannes, Xiang-Yi Li, Marc Pesant, Hongjuan Zhao, Kozo Akasaka, Francis Fang
  • Intermediates for the Preparation of Halichondrin B
    Publication number: 20070244187
    Abstract: The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).
    Type: Application
    Filed: June 3, 2005
    Publication date: October 18, 2007
    Applicant: Eisai Co., Ltd
    Inventors: Brian Austad, Charles Chase, Francis Fang